Staphylococcus aureus in early cystic fibrosis lung disease

Pediatr Pulmonol. 2013 Dec;48(12):1151-9. doi: 10.1002/ppul.22863. Epub 2013 Aug 22.


Staphylococcus aureus: is a common bacterial organism infecting children with cystic fibrosis (CF). Emerging evidence suggests early lower airway infection with this organism in young children with CF results in the deterioration of lung function, poorer nutrition parameters and heightens the airway inflammatory response. Despite contributing significantly to the burden of early lung disease among this group, there are ongoing controversies in the management of S. aureus infection, and gaps in our understanding of exactly how this organism causes lung disease. To reduce the morbidity and mortality of early infection ongoing research is needed to: (i) understand the early host immune response that enables this pathogen to reside within the CF lung; (ii) determine if there are organism specific factors that are associated with CF lung disease; and (iii) clarify the utility of anti-staphylococcal antibiotic prophylaxis and/or eradication in the treatment of this patient population.

Keywords: S. aureus; cystic fibrosis.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Child
  • Cystic Fibrosis / complications
  • Cystic Fibrosis / drug therapy
  • Cystic Fibrosis / physiopathology*
  • Humans
  • Pneumonia, Staphylococcal / complications
  • Pneumonia, Staphylococcal / drug therapy
  • Pneumonia, Staphylococcal / physiopathology*
  • Respiratory Tract Infections / complications
  • Respiratory Tract Infections / drug therapy
  • Respiratory Tract Infections / physiopathology
  • Staphylococcal Infections / complications
  • Staphylococcal Infections / drug therapy
  • Staphylococcal Infections / physiopathology
  • Staphylococcus aureus*


  • Anti-Bacterial Agents